Bayer Aktie
| 18,83EUR | -0,03EUR | -0,14% |
WKN DE: BAY001 / ISIN: DE000BAY0017
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 100,00 |
| Norges Bank Investment Management | 3,15 |
| Silchester International Investors LLP | 3,00 |
| Temasek Holdings Pte Ltd. (Investment Management) | 3,00 |
| Amundi Asset Management SA (Investment Management) | 2,89 |
| Government Pension Fund - Global (The) | 2,51 |
| Oakmark International Fund | 2,06 |
| Dodge & Cox International Stock Fund | 1,71 |
| Vanguard Total International Stock Index Fund | 1,40 |
| Vanguard Developed Markets Index Fund | 0,86 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 103 824 | 99 538 | 99 637 | 101 369 | 99 723 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,42 | 0,42 | 0,44 | 0,50 | 0,48 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 31 760 | 35 002 | 31 994 | 37 247 | 37 090 |
| Summe Anlagevermögen | 99 567 | 87 848 | 94 784 | 93 637 | 86 254 |
| Summe Aktiva | 131 327 | 122 850 | 126 778 | 130 884 | 123 344 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 83 810 | 92 151 | 93 610 | 91 958 | 90 266 |
| Summe Eigenkapital | 47 517 | 30 699 | 33 168 | 38 926 | 33 078 |
| Summe Passiva | 131 327 | 122 850 | 126 778 | 130 884 | 123 344 |
Adresse
| Kaiser-Wilhelm-Allee 1, 51368 Leverkusen | |
| Telefon | +49 (214) 30-1 |
| Internet | http://www.bayer.com |
Management
|
Alan Schultz
Head-North America Project Procurement |
|
Alberto Weisser
Independent Member-Supervisory Board |
|
Andrea Sacher
Member-Supervisory Board |
|
André van Broich
Member-Supervisory Board |
|
Barbara Gansewendt
Member-Supervisory Board |
|
Bijoy Sagar
Chief Information Technology Officer |
|
Brad Griffith
Vice President |
|
Christian Rommel
EVP, Head-Research & Development |
|
Christine Roth
Executive VP-Oncology Strategic Business |
|
Claudia Schade
Member-Supervisory Board |
|
Colleen A. Goggins
Independent Member-Supervisory Board |
|
Ertharin Cousin
Independent Member-Supervisory Board |
|
Francesco Grioli
Member-Supervisory Board |
|
Frank Löllgen
Member-Supervisory Board |
|
Heike Hausfeld
Vice Chairman-Supervisory Board |
|
Heike Prinz
Member-Management Board |
|
Heinz Georg Webers
Member-Supervisory Board |
|
Horst Heinz Paul Baier
Independent Member-Supervisory Board |
|
Itziar Canamasas
Head-Oncology Europe, Middle East & Africa |
|
Jeffrey Williams Ubben
Member-Supervisory Board |
|
Julio Triana
President-Consumer Health Division |
|
Jürgen Eckhardt
Head-Business Development & Licensing |
|
Kimberly Marie Lein-Mathisen
Independent Member-Supervisory Board |
|
Lori A. Schechter
Member-Supervisory Board |
|
Markus Siebenmorgen
Head-Human Resources & Social Services |
|
Michael Westmeier
Member-Supervisory Board |
|
Miriam Holstein
Head-Corporate Office |
|
Nancy A. Simonian
Member-Supervisory Board |
|
Norbert Winkeljohann
Chairman-Supervisory Board |
|
Paul Achleitner
Member-Supervisory Board |
|
Philipp Blank
Head-Law, Compliance & Information Technology |
|
Rodrigo Santos
President-Crop Science Division |
|
Ruzha Draganova
Global HR Business Partner |
|
Stefan Oelrich
President-Pharmaceuticals Division |
|
Thomas Hoffmann
Head-Treasury |
|
Thomas Kornek
Vice President-Investor Relations |
|
William N. Anderson
Chief Executive Officer |
|
Wolfgang U. Nickl
Head-Finance |
|
Yasmin Fahimi
Member-Supervisory Board |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
